Phase I/II study of TAS-120

PHASE 1/2 STUDY OF TAS-120 IN PATIENTS WITH ADVANCED SOLID TUMORS HARBORING FGF/FGFR ABERRATIONS

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080224117

Enrollment

Registered

2018-10-29

Start date

2018-07-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

solid tumors

Interventions

investigational material(s) Generic name etc : TAS-120 : futibatinib INN of investigational material : TAS-120 : futibatinib Therapeutic category code : 429 Other antitumor agents Dosage and Administr

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Provide written informed consent. 2. Is >= 20 years. 3. Has histologically or cytologically confirmed, locally advanced, metastatic cancer. 4. Patient has measurable disease. 5. ECOG performance status 0 or 1. 6. Able to take medications orally. 7. Adequate organ function. 8. Have a negative pregnancy test. 9. Willing and able to comply with scheduled visits and study procedures.

Exclusion criteria

Exclusion criteria: 1. History and/or current evidence of non-tumor related alteration of calcium-phosphorus homeostasis. 2. History and/or current evidence of clinically significant ectopic mineralization/calcification. 3. History and/or current evidence of clinically significant retinal disorder confirmed by retinal examination. 4. A serious illness or medical condition(s)

Design outcomes

Primary

Measure	Time frame
safety efficacy Safety, Efficacy	—

Secondary

Measure	Time frame
safety efficacy Safety, Efficacy CTCAE(version 4.03), RECIST(version 1.1)	—

Countries

Asia except Japan, Europe, Japan, North America, Oceania

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026